GENNO-INZhENERNYE BIOLOGIChESKIE PREPARATY V TERAPII OSTEOPOROZA U BOL'NYKhREVMATOIDNYM ARTRITOM

Abstract

The authors review the current literature data on the influence of the genetically engineered biological drugs on the bone mineral density, bone exchange and remodeling of bone are submitted. Due to high efficiency these drugs received the deserved popularity in spite of the fact that are applied in rheumatology rather recently. The leading role in pathogenesis of local and generalized bone resorption and destruction in rheumatoid arthritis is realized by mediators of immune and inflammatory processes (pro-inflammatory cytokinins): tumor necrosis factor a, interleukin 1, 2, 12, 17, interferon γ, and also prostaglandins, proteolytic enzymes (a collagenase, other proteases), etc. There are described RANKL — dependent and RANKL — independent mechanisms of activation the osteoclastogenesis. In recent years it is established that the inhibition of pro-inflammatory cytokinins not only reduces inflammatory changes of joints, but also constrains destruction development, interferes with development of bone erosions and generalized bone loss. In the present review results of these works are discussed and questions for future researches are brought up.

Keywords

• ревматоидный артрит
• генно-инженерные биологические препараты
• патогенез локальной и генерализованной резорбции
• факторы риска вторичного остеопороза
• минеральная плотность кости
• переломы